Raza Ur Rahman, PhD
Founder & CEO- Built RNA discovery platforms Oasis 2, SEAweb and Singletrome
- Co-author, TILAM discovery paper (Hepatology, 2024)
- Harvard · Broad · MGH · UMass Chan
- Consultant to biotech drug discovery programs
Scar tissue replaces working tissue in the liver, lung, kidney and heart, building toward cirrhosis, organ failure and transplant. Approved therapies slow the injury that drives scarring, but none switches off the scar-forming program itself. Every approved therapy was built on a protein target, and less than 2% of the genome codes for protein.
The rest is transcribed into RNA that helps decide which cells turn fibrotic. Much of it is specific to a single cell type, which makes it both a precise target and easy to miss.
Small molecules need a pocket. Biologics stay outside the cell. RNA needs only a sequence. Of 20,300 protein-coding genes, only 4,479 are druggable.1 RNA medicines act on the instructions inside the cell.
Making the drug is no longer the hard part. Choosing the target is.
See how we chooseFibrosis is the shared end point of chronic disease in the liver, lung, kidney and heart, and no approved medicine switches off the scar-forming program itself.
In liver fibrosis, the Apertome Engine ranked more than 110,000 genes and prioritized 69 cell-type-specific targets for our first program.
View the programA lncRNA published in Hepatology (2024). TILAM was not discovered by the Apertome Engine. It shows that a cell-type-specific non-coding RNA can drive fibrosis and be targeted, the premise our platform and fibrosis program are built on.
We have access to liver fibrosis patients across the stages of the disease. Every prioritized target will be tested in patient tissue before a molecule is designed.
Three RNA classes, coding and non-coding, scored side by side in the same single-cell and bulk RNA data.
Targets are ranked by how specific they are to the cells driving disease, then matched to delivery into that cell type, so the medicine acts where it matters and spares healthy tissue.
The same engine applies to any tissue with single-cell data. Fibrosis is our first indication.
Disease starts when specific cells change state. The Apertome Engine finds the RNA that controls that change, cell type by cell type, and pairs each target with delivery into the cell type that expresses it.
Protein-coding genes are a small part of the genome. The non-coding majority is the instruction layer that sets cell identity and behavior. We annotate and quantify three RNA classes, mRNA, long non-coding RNA and microRNA, in the same single-cell and bulk RNA data, so every candidate is compared on equal terms.
We profile healthy and diseased tissue with single-cell sequencing to resolve cell types, and bulk RNA sequencing for depth. The Apertome Engine's proprietary annotation captures coding and non-coding transcripts that standard references miss. Every RNA is assigned to the cell types that express it, from stellate-cell drivers of fibrosis to hepatocyte-specific lncRNAs.
Every transcript is scored on cell-type specificity, association with disease and druggability by RNA medicines. Specificity comes first: a target confined to the disease-driving cell is a target with fewer side effects in healthy tissue.
Each target is paired with a delivery route into the cell type that expresses it. We start in hepatocytes, where GalNAc conjugates already deliver approved RNA medicines, and extend to stellate cells as delivery to them matures.
Each target is silenced in human liver organoids, with chemistry matched to where the RNA sits: antisense oligonucleotides for nuclear lncRNAs, siRNA for RNA in the cytoplasm. We then measure whether the scarring program switches off and reverses, and targets that do advance to in vivo models.
lncRNAs are 46 of our 69 prioritized targets. Most pipelines never score them because standard annotations miss them.
A target confined to the disease-driving cell starts with a safety advantage. We rank for that first.
Every target is matched to a delivery route into its cell type, so the shortlist is a list of medicines that can reach their cells.
Every prioritized target is tested in patient tissue before a molecule is designed.
TILAM is a long non-coding RNA. Published in Hepatology (2024), it is expressed predominantly in the stellate cells that make the scar in the injured liver, and depleting it protected against fibrosis in human stellate cells, human liver organoids and mouse models.
It validates the RNA class and the indication. It is the reference point for the cell-type-specific targets the Apertome Engine now finds at scale.
Read the TILAM paper ↗A genome annotation of 110,599 genes, protein-coding and lncRNA, built for single-cell data. It resolves lncRNA expression by cell type and showed lncRNAs alone can identify cell types and disease.
Read paper ↗A web application for detection, differential expression and classification of small RNAs in sequencing data, including novel miRNAs across 14 organisms.
Read paper ↗The Small RNA Expression Atlas: over 4,200 published samples across 10 organisms, re-analyzed and searchable, with 591 tissue-specific miRNAs identified.
Read paper ↗Our first program silences disease-driving genes in specific liver cell types, using RNA specific to those cells. We start where RNA delivery is already clinically proven, so the path to the clinic is shorter.
Fibrosis stage is the strongest predictor of liver-related death.1 The two approved MASH therapies act upstream, on the metabolic injury that provokes scarring. No approved therapy switches off the scar-forming program itself. Our target patients are adults with MASH and moderate to advanced fibrosis (F2–F3), the stage at which fibrosis drives outcomes and treatment is indicated.
Proven route. Our first targets are expressed in hepatocytes, where delivery of RNA medicines is clinically validated: GalNAc conjugation is used by seven of the eight approved siRNAs. In phase 2 SEQUOIA, the GalNAc-siRNA fazirsiran lowered its hepatocyte target in serum and in liver tissue and reduced the misfolded Z-AAT protein globules in the liver on paired pre-treatment and post-treatment biopsies.2
Already in MASH. ION224, an antisense oligonucleotide against DGAT2, met its primary endpoint in a 51-week phase 2 trial in MASH with F1 to F3 fibrosis, in 46% and 59% of patients at the two doses against 19% on placebo.3
Next. Targets in hepatic stellate cells, the cells that make the scar, follow as delivery to them matures across the field.
The Apertome Engine scored 110k+ genes across single-cell and bulk human liver datasets and prioritized 69 cell-type-specific targets. Chemistry is matched to where each RNA sits: antisense oligonucleotides for nuclear lncRNAs, siRNA for RNA in the cytoplasm. Both chemistries have approved medicines behind them.
Each target is silenced in human liver organoids and measured for whether the scarring program switches off and reverses, and the strongest advance to in vivo models. Testing in human tissue gives early efficacy signals, and clinical studies will pair histology with non-invasive fibrosis markers.
We have access to liver fibrosis patients and their biopsies, blood samples and clinical data across the stages of the disease. Every prioritized target will be tested in patient tissue before a molecule is designed.
TILAM, a published lncRNA target in liver fibrosis (Hepatology, 2024), is expressed predominantly in the stellate cells that make the scar in the injured liver, and depleting it protected against fibrosis in human stellate cells, human liver organoids and mouse models. It is not an Apertome program; it is the benchmark ours are measured against.
Read the TILAM paper ↗We are building the company that finds and drugs the RNA controlling disease in the cells where it starts, beginning with fibrosis, the end point of chronic disease that no approved medicine switches off.
The page you were looking for has moved or does not exist.
Apertome Therapeutics collects only the information you choose to send us, such as your name, email address, organization and message when you use our contact form or email us.
We use this information to respond to your inquiry. We do not sell or share it with third parties for marketing. You can ask us to access, correct or delete your information at any time by writing to raza@apertometx.com.
Apertome Therapeutics · Boston, Massachusetts
For investment, partnership or scientific collaboration.
We'll be in touch shortly.